NOV.DE vs. 4AB.DE
Compare and contrast key facts about Novo Nordisk A/S (NOV.DE) and AbbVie Inc (4AB.DE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NOV.DE or 4AB.DE.
Key characteristics
| NOV.DE | 4AB.DE | |
|---|---|---|
| YTD Return | 16.00% | 39.21% |
| 1Y Return | 15.82% | 51.78% |
| 3Y Return (Ann) | 38.78% | 27.98% |
| 5Y Return (Ann) | 47.30% | 25.26% |
| 10Y Return (Ann) | 42.60% | 18.87% |
| Sharpe Ratio | 0.62 | 2.65 |
| Sortino Ratio | 1.10 | 3.57 |
| Omega Ratio | 1.13 | 1.45 |
| Calmar Ratio | 0.72 | 3.11 |
| Martin Ratio | 1.97 | 11.42 |
| Ulcer Index | 9.67% | 4.53% |
| Daily Std Dev | 30.72% | 19.88% |
| Max Drawdown | -50.94% | -36.94% |
| Current Drawdown | -25.39% | -2.57% |
Fundamentals
| NOV.DE | 4AB.DE | |
|---|---|---|
| Market Cap | €444.92B | €331.44B |
| EPS | €2.84 | €2.66 |
| PE Ratio | 35.24 | 70.51 |
| PEG Ratio | 1.64 | 0.47 |
| Total Revenue (TTM) | €85.63B | €41.07B |
| Gross Profit (TTM) | €72.69B | €27.07B |
| EBITDA (TTM) | €44.45B | €14.78B |
Correlation
The correlation between NOV.DE and 4AB.DE is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NOV.DE vs. 4AB.DE - Performance Comparison
In the year-to-date period, NOV.DE achieves a 16.00% return, which is significantly lower than 4AB.DE's 39.21% return. Over the past 10 years, NOV.DE has outperformed 4AB.DE with an annualized return of 42.60%, while 4AB.DE has yielded a comparatively lower 18.87% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NOV.DE vs. 4AB.DE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NOV.DE) and AbbVie Inc (4AB.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NOV.DE vs. 4AB.DE - Dividend Comparison
NOV.DE's dividend yield for the trailing twelve months is around 1.33%, less than 4AB.DE's 3.05% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NOV.DE Novo Nordisk A/S | 1.33% | 1.01% | 1.18% | 1.27% | 1.99% | 2.09% | 5.96% | 2.28% | 3.69% | 1.25% | 1.69% | 1.82% |
4AB.DE AbbVie Inc | 3.05% | 3.87% | 3.53% | 3.67% | 4.88% | 4.31% | 3.54% | 2.73% | 3.26% | 0.00% | 0.00% | 0.00% |
Drawdowns
NOV.DE vs. 4AB.DE - Drawdown Comparison
The maximum NOV.DE drawdown since its inception was -50.94%, which is greater than 4AB.DE's maximum drawdown of -36.94%. Use the drawdown chart below to compare losses from any high point for NOV.DE and 4AB.DE. For additional features, visit the drawdowns tool.
Volatility
NOV.DE vs. 4AB.DE - Volatility Comparison
The current volatility for Novo Nordisk A/S (NOV.DE) is 4.06%, while AbbVie Inc (4AB.DE) has a volatility of 7.35%. This indicates that NOV.DE experiences smaller price fluctuations and is considered to be less risky than 4AB.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NOV.DE vs. 4AB.DE - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and AbbVie Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities